Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developing a successful vaccine to control the HIV pandemic. Historically, HIV vaccine regimens have been tested in NHPs by administering a single high dose of the challenge virus. More recently, evaluation of candidate HIV vaccines has entailed repeated low-dose challenges which more closely mimic typical exposure in natural transmission settings. In this paper, we consider evaluation of the type and magnitude of vaccine efficacy from such experiments. Based on the principal stratification framework, we also address evaluation of potential immunological surrogate endpoints for infection
HIV vaccines possessing only modest, or even poor, ability to reduce susceptibility to infection cou...
BACKGROUND: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No ...
Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No ...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus p...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
Trials in macaque models play an essential role in the evaluation of biomedical interventions that a...
<div><p>To assess the efficacy of HIV vaccine candidates or preventive treatment, many research grou...
Historically, HIV vaccines specifically designed to raise cellular immunity resulted in protection f...
This article introduces methods for use in vaccine clinical trials to help determine whether the imm...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
Many HIV vaccine trials have been proposed to evaluate susceptibility of individuals. However, vac c...
HIV vaccines possessing only modest, or even poor, ability to reduce susceptibility to infection cou...
BACKGROUND: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No ...
Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No ...
Evaluation of HIV vaccine candidates in non-human primates (NHPs) is a critical step toward developi...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus (...
A critical step toward developing a successful vaccine to control the human immunodeficiency virus p...
Simulation studies were conducted to estimate the statistical power of repeated low-dose challenge e...
Trials in macaque models play an essential role in the evaluation of biomedical interventions that a...
<div><p>To assess the efficacy of HIV vaccine candidates or preventive treatment, many research grou...
Historically, HIV vaccines specifically designed to raise cellular immunity resulted in protection f...
This article introduces methods for use in vaccine clinical trials to help determine whether the imm...
Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine...
Many HIV vaccine trials have been proposed to evaluate susceptibility of individuals. However, vac c...
HIV vaccines possessing only modest, or even poor, ability to reduce susceptibility to infection cou...
BACKGROUND: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No ...
Background: More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No ...